Biogen【0R1B】銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

277.67

買値

0.00

売値

0.00

出来高

2,481

0.00 日の範囲 0.00

277.67 52 週間の範囲 277.67

時価総額

40.462B

前日終値

277.67

始値

時刻

140.0168

(O)

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

3,534

発行済株式数

145,719,000

配当利回り

PER

12.50

1 株当たり利益 (EPS)

11.2

歳入

9.68B

純利益

1.63B

セクター

Biological Pds,ex Diagnstics

業界

Biological Pds,ex Diagnstics

ウェブサイト

www.biogen.com

本社

Wilmington, Delaware, USA

設立

Biogen Inc is listed in the Biological Pds,ex Diagnstics sector of the ロンドン証券取引所 with ticker 0R1B. The last closing price for Biogen was US$277.67. Over the last year, Biogen shares have traded in a share price range of US$ 277.67 to US$ 277.67.

Biogen currently has 145,719,000 shares in issue. The market capitalisation of Biogen is US$40.46 billion. Biogen has a price to earnings ratio (PE ratio) of 12.50.

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients Global...

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare...

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE...

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Once every four weeks maintenance...

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA Applications are based on data from the DEVOTE study, which...

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s...

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus...

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease TOKYO and CAMBRIDGE, Mass., Nov...

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD...

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and...

期間 †	始値	高値	安値	平均出来高	VWAP
1	277.67	277.67	277.67	3470	277.67	DE
4	277.67	277.67	277.67	2856	277.67	DE
12	277.67	277.67	277.67	3534	277.67	DE
26	277.67	277.67	277.67	4201	277.67	DE
52	277.67	277.67	277.67	3704	277.67	DE
156	277.67	277.67	277.67	4469	277.67	DE
260	277.67	277.67	277.67	4021	277.67	DE

0R1B - Frequently Asked Questions (FAQ)

What is the current Biogen share price?

The current share price of Biogen is US$ 277.67

How many Biogen shares are in issue?

Biogen has 145,719,000 shares in issue

What is the market cap of Biogen?

The market capitalisation of Biogen is USD 40.46B

What is the 1 year trading range for Biogen share price?

Biogen has traded in the range of US$ 277.67 to US$ 277.67 during the past year

What is the PE ratio of Biogen?

The price to earnings ratio of Biogen is 12.5

What is the cash to sales ratio of Biogen?

The cash to sales ratio of Biogen is 2.11

What is the reporting currency for Biogen?

Biogen reports financial results in USD

What is the latest annual turnover for Biogen?

The latest annual turnover of Biogen is USD 9.68B

What is the latest annual profit for Biogen?

The latest annual profit of Biogen is USD 1.63B

What is the registered address of Biogen?

The registered address for Biogen is 3411 SILVERSIDE ROAD TATNALL, BUILDING #104, NEW CASTLE, WILMINGTON, DELAWARE, 19810

What is the Biogen website address?

The website address for Biogen is www.biogen.com

Which industry sector does Biogen operate in?

Biogen operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
CPAICapai Plc	0.1175p (40.72%)	901.7M
XTRXtract Resources Plc	0.75p (36.36%)	9.04M
EUAEurasia Mining Plc	7.40p (32.14%)	38.22M
STBSecure Trust Bank Plc	540.00p (28.57%)	560.29k
HAYDHaydale Graphene Industries Plc	0.1325p (20.45%)	60.48M
ONCOncimmune Holdings Plc	1.15p (-27.67%)	662.94k
HRNHornby Plc	14.00p (-26.32%)	847.78k
THRUThruvision Group Plc	0.65p (-23.53%)	36.04M
DISDistil Plc	0.065p (-21.21%)	5.94M
SYMESupply@me Capital Plc	0.003p (-20.00%)	340.56M
UKOGUk Oil & Gas Plc	0.0105p (10.53%)	906.2M
CPAICapai Plc	0.1175p (40.72%)	901.7M
PREMPremier African Minerals Limited	0.01025p (-3.30%)	610.07M
ENETEthernity Networks Ltd	0.0625p (-7.41%)	484.96M
EMEEmpyrean Energy Plc	0.1225p (0.00%)	340.91M

Good time Charlie 3分前

Your just down the road from me.

VDRM

Remember Tomorrow 4分前

Eating seeds is a past time activity.

Remember Tomorrow

SHIBUSD

DTGoody 4分前

I sure hope so. Our PPS makes no sense at all even with a 2 billion OS.

Many other companies with far less potential are trading at much higher levels than we are.

AFFU

RREAGAN 4分前

THE PUMP SHAL COMMETH

SSP

littlejohn 4分前

Intel may be getting pumped now to try

to help prop up some averages...

It is a cheaper price company in SPX and

Nasdaq for market makers to pump up,

still holding SMCI because of being a

bag holder with hopes for better...

SMCI

2can$ 6分前

I have faults to......vive DBMM$

DBMM

Boat Shoes From Yahoo 6分前

Boom!

-Boat

FNMA

blownaccount9 7分前

Unsure because valuation would be crazy. Maybe just change the strike price of the warrants to $5 and call it good. Otherwise if they’d cancel half the warrants that would be insane too.

FNMA

Dead On Arrival 8分前

0 and you are a fraud as well.

LWLG

KCCO7913 8分前

Ahh that was you over on the other forum! I'll definitely have a beer with you in May. I am actually a bit surprised Yves mentioned that datapoint. It's been the big question all along.

What portion of the value of a transceiver is the modulator?

I need to listen agai

LWLG

Lime Time 8分前

2.93/gal here. Been the cheapest gas in over 4 years. I'll take a pic of it tomorrow.

Because you people don't believe in facts. Anything that goes against your agenda, you deny.

Paulie Cashews 9分前

Safari couldn't locate the server?
Why doesn't Safari take its own advice and keep going on safari to locate that damn server?

adserv.stocksite.com/images/paulie/ihoops.jpg

www.investorshub.com/boards/board.asp?board_id=2581 Paulie's Pixel Palace

BOREALIS 9分前

Trump’s message following Elon Musk’s $29 billion loss in a single day

Story by Fredrik Falk • 12h

Elon Musk is having a rough time lately, especially with Tesla’s stock taking a serious hit.

In fact, his friend Donald Trump had to step in and defend him

2can$ 9分前

You are the big shining star barber and I do love you with all your faults.

March forward in your endeavor here I am comfortable enough here that all now your motivations towards DBMM.

Find yourself sooner rather then later, be well sir.

DBMM

Dead On Arrival 9分前

Did not listen to the call. As soon as I saw that weasel Marceli was repping the company at the next conference, I sold my options. Let us see what tomorrow holds but it would appear that 1 is a very good possibility. Guessing we get booted from the indexes and a r/s is in the cards. Only way to con

LWLG

Lifetime 10分前

I also cannot understand how people think that there is one guy huddled around a computer making trades on a $0.000x stock and getting signals from another guy huddled around a computer making trades.
With the BILLIONS of stock shares traded a day.... maybe; just maybe there is a computer al

BIEL

janice shell 10分前

LOLOLOLOL!!

seve333 10分前

Where is Mr stockboy he said this stock was going to 100 a share.

AMRN

Stks_Not_Toys 11分前

You're accusing me of oxymoronicness?

You made the agitational exclamatory statement with the words hate and untrustworthy.

Ricco79 12分前

Is it theoretically possible for Pulte and the government to offer the 80% warrants for repurchase by Fannie and Freddie over the next 4 years, for example, at the current price if the SPS is declared paid or illegal?

FNMA

arizona1 13分前

Did you notice gas prices are getting cheaper?

I paid $1 more than I did three months ago. You're a liar.

Gas prices are rising, with the national average currently above $3.10 per gallon, and the West Coast, including Arizona, experiencing some of the highest prices i

janice shell 14分前

No it isn't. He did not run on imposing tariffs. Tariffs are a tax on consumers.

They do not benefit anyone. See the Smoot-Hawley Act and what it led to.

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Biogen Inc (0R1B)

個人投資家向けのプロ仕様のツール。

主要統計と詳細

Biogen Inc について

0R1B 最新ニュース

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

0R1B - Frequently Asked Questions (FAQ)

ムーバー

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Biogen Inc (0R1B) 銘柄情報

Biogen Inc (0R1B)

個人投資家向けのプロ仕様のツール。

主要統計と詳細

Biogen Inc について

0R1B 最新ニュース

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

0R1B - Frequently Asked Questions (FAQ)

ムーバー

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

広告を削除する